MedPath

Study to describe the processing of ropivacaine in the body when injected in the knee for pain treatment in total knee replacement surgery

Completed
Conditions
patients requiring unilateral total knee replacement
Registration Number
NL-OMON21012
Lead Sponsor
Sint Maartenskliniek Nijmegen
Brief Summary

Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

age 50-80 years

- ASA physical Health Classification I-II

Exclusion Criteria

- Placement of a surgical drain

- Contra-indications for spinal anesthesia

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mean total and unbound maximum serum concentration of ropivacaine (Cmax) and mean time to total and unbound maximum serum concentration of ropivacaine (Tmax)
Secondary Outcome Measures
NameTimeMethod
Age, weight, height, gender, co-medication, complications and signs of systemic toxicity will be recorded.
© Copyright 2025. All Rights Reserved by MedPath